Advertisement

Intermittent Claudication

  • E. Sebastian Debus
  • Reinhart T. Grundmann
Chapter

Abstract

Patients with intermittent claudication should primarily be offered supervised exercise training. Endovascular revascularization is considered when exercise fails to achieve an adequate symptomatic improvement. Open surgery is only the third option, recommended when the alternative treatment options are logistically or technically unfeasible or have proven unsuccessful.

Keywords

Peripheral Arterial Disease Target Lesion Revascularization Peripheral Arterial Disease Patient Femoropopliteal Artery Endovascular Revascularization 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.

References

  1. Aherne T, McHugh S, Kheirelseid EA, Lee MJ, McCaffrey N, Moneley D, Leahy AL, Naughton P. Comparing supervised exercise therapy to invasive measures in the management of symptomatic peripheral arterial disease. Surg Res Pract. 2015;2015:960402.PubMedPubMedCentralGoogle Scholar
  2. Al-Jundi W, Madbak K, Beard JD, Nawaz S, Tew GA. Systematic review of home-based exercise programmes for individuals with intermittent claudication. Eur J Vasc Endovasc Surg. 2013;46:690–706.CrossRefPubMedGoogle Scholar
  3. Ambler GK, Radwan R, Hayes PD, Twine CP. Atherectomy for peripheral arterial disease. Cochrane Database Syst Rev. 2014;3:CD006680.Google Scholar
  4. Anderson JL, Halperin JL, Albert NM, et al. Management of patients with peripheral artery disease (compilation of 2005 and 2011 ACCF/AHA guideline recommendations): a report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines. Circulation. 2013;127:1425–43.CrossRefPubMedGoogle Scholar
  5. Andras A, Hansrani M, Stewart M, Stansby G. Intravascular brachytherapy for peripheral vascular disease. Cochrane Database Syst Rev. 2014;(1):CD003504.Google Scholar
  6. Bulińska K, Kropielnicka K, Jasiński T, et al. Nordic pole walking improves walking capacity in patients with intermittent claudication: a randomized controlled trial. Disabil Rehabil. 2016;38:1318–24.CrossRefPubMedGoogle Scholar
  7. Chowdhury MM, McLain AD, Twine CP. Angioplasty versus bare metal stenting for superficial femoral artery lesions. Cochrane Database Syst Rev. 2014;(6):CD006767.Google Scholar
  8. Conte MS, Pomposelli FB, Clair DG, et al. ; Society for Vascular Surgery Lower Extremity Guidelines Writing Group. Society for vascular surgery practice guidelines for atherosclerotic occlusive disease of the lower extremities: management of asymptomatic disease and claudication. J Vasc Surg. 2015;61(3 Suppl):2S–41S.Google Scholar
  9. Dake MD, Ansel GM, Jaff MR, et al. ; Zilver PTX investigators. Durable clinical effectiveness with paclitaxel-eluting stents in the femoropopliteal artery: 5-year results of the Zilver PTX randomized trial. Circulation. 2016;133:1472–83.Google Scholar
  10. Fakhry F, Rouwet EV, den Hoed PT, Hunink MG, Spronk S. Long-term clinical effectiveness of supervised exercise therapy versus endovascular revascularization for intermittent claudication from a randomized clinical trial. Br J Surg. 2013;100:1164–71.CrossRefPubMedGoogle Scholar
  11. Fakhry F, Spronk S, van der Laan L, et al. Endovascular Revascularization and Supervised Exercise for peripheral artery disease and intermittent claudication: a randomized clinical trial. JAMA. 2015;314:1936–44.CrossRefPubMedGoogle Scholar
  12. Fokkenrood HJ, Bendermacher BL, Lauret GJ, Willigendael EM, Prins MH, Teijink JA. Supervised exercise therapy versus non-supervised exercise therapy for intermittent claudication. Cochrane Database Syst Rev. 2013;(8):CD005263.Google Scholar
  13. Fokkenrood HJ, Lauret GJ, Verhofstad N, Bendermacher BL, Scheltinga MR, Teijink JA. The effect of supervised exercise therapy on physical activity and ambulatory activities in patients with intermittent claudication. Eur J Vasc Endovasc Surg. 2015;49:184–91.CrossRefPubMedGoogle Scholar
  14. Frans FA, Bipat S, Reekers JA, Legemate DA, Koelemay MJ. Systematic review of exercise training or percutaneous transluminal angioplasty for intermittent claudication. Br J Surg. 2012;99:16–28.CrossRefPubMedGoogle Scholar
  15. Gardner AW, Montgomery PS, Parker DE. Optimal exercise program length for patients with claudication. J Vasc Surg. 2012;55:1346–54.CrossRefPubMedPubMedCentralGoogle Scholar
  16. Gardner AW, Parker DE, Montgomery PS, Blevins SM. Diabetic women are poor responders to exercise rehabilitation in the treatment of claudication. J Vasc Surg. 2014;59:1036–43.CrossRefPubMedGoogle Scholar
  17. Geraghty PJ, Mewissen MW, Jaff MR, Ansel GM; VIBRANT Investigators. Three-year results of the VIBRANT trial of VIABAHN endoprosthesis versus bare nitinol stent implantation for complex superficial femoral artery occlusive disease. J Vasc Surg. 2013;58:386–95.Google Scholar
  18. Gommans LN, Saarloos R, Scheltinga MR, Houterman S, de Bie RA, Fokkenrood HJ, Teijink JA. Editor’s choice–the effect of supervision on walking distance in patients with intermittent claudication: a meta-analysis. Eur J Vasc Endovasc Surg. 2014;48:169–84.CrossRefPubMedGoogle Scholar
  19. Gommans LN, Fokkenrood HJ, van Dalen HC, Scheltinga MR, Teijink JA, Peters RJ. Safety of supervised exercise therapy in patients with intermittent claudication. J Vasc Surg. 2015a;61:512–8.CrossRefPubMedGoogle Scholar
  20. Gommans LN, Scheltinga MR, van Sambeek MR, Maas AH, Bendermacher BL, Teijink JA. Gender differences following supervised exercise therapy in patients with intermittent claudication. J Vasc Surg. 2015b;62:681–8.CrossRefPubMedGoogle Scholar
  21. Gommans LN, Teijink JA. Attitudes to supervised exercise therapy. Br J Surg. 2015;102:1153–5.CrossRefPubMedGoogle Scholar
  22. Jens S, Conijn AP, Koelemay MJ, Bipat S, Reekers JA. Randomized trials for endovascular treatment of infrainguinal arterial disease: systematic review and meta-analysis (Part 1: Above the knee). Eur J Vasc Endovasc Surg. 2014;47:524–35.CrossRefPubMedGoogle Scholar
  23. Katsanos K, Spiliopoulos S, Karunanithy N, Krokidis M, Sabharwal T, Taylor P. Bayesian network meta-analysis of nitinol stents, covered stents, drug-eluting stents, and drug-coated balloons in the femoropopliteal artery. J Vasc Surg. 2014;59:1123–33.CrossRefPubMedGoogle Scholar
  24. Katsanos K, Geisler BP, Garner AM, Zayed H, Cleveland T, Pietzsch JB. Economic analysis of endovascular drug-eluting treatments for femoropopliteal artery disease in the UK. BMJ Open. 2016a;6:e011245.CrossRefPubMedPubMedCentralGoogle Scholar
  25. Katsanos K, Spiliopoulos S, Paraskevopoulos I, Diamantopoulos A, Karnabatidis D. Systematic review and meta-analysis of randomized controlled trials of paclitaxel-coated balloon angioplasty in the femoropopliteal arteries: role of paclitaxel dose and bioavailability. J Endovasc Ther. 2016b;23:356–70.CrossRefPubMedGoogle Scholar
  26. Laird JR, Katzen BT, Scheinert D et al. ; RESILIENT Investigators. Nitinol stent implantation vs. balloon angioplasty for lesions in the superficial femoral and proximal popliteal arteries of patients with claudication: three-year follow-up from the RESILIENT randomized trial. J Endovasc Ther. 2012;19:1–9.Google Scholar
  27. Laird JR, Schneider PA, Tepe G, et al. ; IN.PACT SFA Trial Investigators. Durability of treatment effect using a drug-coated balloon for femoropopliteal lesions: 24-month results of IN.PACT SFA. J Am Coll Cardiol. 2015;66: 2329–38.Google Scholar
  28. Lammer J, Zeller T, Hausegger KA, et al. Sustained benefit at 2 years for covered stents versus bare-metal stents in long SFA lesions: the VIASTAR trial. Cardiovasc Intervent Radiol. 2015;38:25–32.CrossRefPubMedGoogle Scholar
  29. Lane R, Ellis B, Watson L, Leng GC. Exercise for intermittent claudication. Cochrane Database Syst Rev. 2014;(7):CD000990.Google Scholar
  30. Lauret GJ, van Dalen HC, Hendriks HJ, van Sterkenburg SM, Koelemay MJ, Zeebregts CJ, Peters RJ, Teijink JA. When is supervised exercise therapy considered useful in peripheral arterial occlusive disease? A nationwide survey among vascular surgeons. Eur J Vasc Endovasc Surg. 2012;43:308–12.CrossRefPubMedGoogle Scholar
  31. Lauret GJ, Fakhry F, Fokkenrood HJ, Hunink MG, Teijink JA, Spronk S. Modes of exercise training for intermittent claudication. Cochrane Database Syst Rev. 2014;(7):CD009638.Google Scholar
  32. Lindgren H, Gottsäter A, Qvarfordt P, Bergman S, Troëng T. Invasive treatment for infrainguinal claudication has satisfactory 1 year outcome in three out of four patients: a population-based analysis from Swedvasc. Eur J Vasc Endovasc Surg. 2014;47:615–20.CrossRefPubMedGoogle Scholar
  33. Malgor RD, Alahdab F, Elraiyah TA, et al. A systematic review of treatment of intermittent claudication in the lower extremities. J Vasc Surg. 2015;61(3 Suppl):54S–73S.CrossRefPubMedGoogle Scholar
  34. Mazari FA, Khan JA, Carradice D, Samuel N, Abdul Rahman MN, Gulati S, Lee HL, Mehta TA, McCollum PT, Chetter IC. Randomized clinical trial of percutaneous transluminal angioplasty, supervised exercise and combined treatment for intermittent claudication due to femoropopliteal arterial disease. Br J Surg. 2012;99:39–48.CrossRefPubMedGoogle Scholar
  35. Mazari FA, Khan JA, Carradice D, Samuel N, Gohil R, McCollum PT, Chetter IC. Economic analysis of a randomized trial of percutaneous angioplasty, supervised exercise or combined treatment for intermittent claudication due to femoropopliteal arterial disease. Br J Surg. 2013;100:1172–9.CrossRefPubMedGoogle Scholar
  36. Murphy TP, Cutlip DE, Regensteiner JG, et al. Supervised exercise, stent revascularization, or medical therapy for claudication due to aortoiliac peripheral artery disease: the CLEVER study. J Am Coll Cardiol. 2015;65:999–1009.CrossRefPubMedPubMedCentralGoogle Scholar
  37. NICE National Institute for Health and Care Excellence. Peripheral arterial disease: diagnosis and management. NICE guidelines [CG147]. 2012. https://www.nice.org.uk/guidance/CG147/chapter/1-Guidance.
  38. Olin JW, White CJ, Armstrong EJ, Kadian-Dodov D, Hiatt WR. Peripheral artery disease: evolving role of exercise, medical therapy, and endovascular options. J Am Coll Cardiol. 2016;67:1338–57.CrossRefPubMedGoogle Scholar
  39. Parmenter BJ, Dieberg G, Phipps G, Smart NA. Exercise training for health-related quality of life in peripheral artery disease: a systematic review and meta-analysis. Vasc Med. 2015;20:30–40.CrossRefPubMedGoogle Scholar
  40. Peeters Weem SM, van Haelst ST, den Ruijter HM, Moll FL, de Borst GJ. Lack of evidence for dual antiplatelet therapy after endovascular arterial procedures: a meta-analysis. Eur J Vasc Endovasc Surg. 2016;52(2):253–62.CrossRefPubMedGoogle Scholar
  41. Reynolds MR, Apruzzese P, Galper BZ, Murphy TP, Hirsch AT, Cutlip DE, Mohler 3rd ER, Regensteiner JG, Cohen DJ. Cost-effectiveness of supervised exercise, stenting, and optimal medical care for claudication: results from the Claudication: exercise versus endoluminal revascularization (CLEVER) trial. J Am Heart Assoc. 2014;3:e001233.CrossRefPubMedPubMedCentralGoogle Scholar
  42. Rosenfield K, Jaff MR, White CJ et al.; LEVANT 2 Investigators. Trial of a paclitaxel-coated balloon for femoropopliteal artery disease. N Engl J Med. 2015;373:145–53.Google Scholar
  43. Sachs T, Pomposelli F, Hamdan A, Wyers M, Schermerhorn M. Trends in the national outcomes and costs for claudication and limb threatening ischemia: angioplasty vs bypass graft. J Vasc Surg. 2011;54:1021–31.CrossRefPubMedGoogle Scholar
  44. Saxton JM, Zwierska I, Blagojevic M, Choksy SA, Nawaz S, Pockley AG. Upper- versus lower-limb aerobic exercise training on health-related quality of life in patients with symptomatic peripheral arterial disease. J Vasc Surg. 2011;53:1265–73.CrossRefPubMedGoogle Scholar
  45. Scheinert D, Duda S, Zeller T, Krankenberg H, Ricke J, Bosiers M, Tepe G, Naisbitt S, Rosenfield K. The LEVANT I (Lutonix paclitaxel-coated balloon for the prevention of femoropopliteal restenosis) trial for femoropopliteal revascularization: first-in-human randomized trial of low-dose drug-coated balloon versus uncoated balloon angioplasty. JACC Cardiovasc Interv. 2014;7:10–9.CrossRefPubMedGoogle Scholar
  46. Simpson EL, Kearns B, Stevenson MD, Cantrell AJ, Littlewood C, Michaels JA. Enhancements to angioplasty for peripheral arterial occlusive disease: systematic review, cost-effectiveness assessment and expected value of information analysis. Health Technol Assess. 2014;18:1–252.CrossRefPubMedPubMedCentralGoogle Scholar
  47. Spafford C, Oakley C, Beard JD. Randomized clinical trial comparing Nordic pole walking and a standard home exercise programme in patients with intermittent claudication. Br J Surg. 2014;101:760–7.CrossRefPubMedGoogle Scholar
  48. Spronk S, Bosch JL, den Hoed PT, Veen HF, Pattynama PM, Hunink MG. Cost-effectiveness of endovascular revascularization compared to supervised hospital-based exercise training in patients with intermittent claudication: a randomized controlled trial. J Vasc Surg. 2008;48:1472–80.CrossRefPubMedGoogle Scholar
  49. Stoner MC, Calligaro KD, Chaer RA, Dietzek AM, Farber A, Guzman RJ, Hamdan AD, Landry GJ, Yamaguchi DJ; Society for Vascular Surgery. Reporting standards of the Society for Vascular Surgery for endovascular treatment of chronic lower extremity peripheral artery disease: executive summary. J Vasc Surg. 2016;64:227–28.Google Scholar
  50. Tendera M, Aboyans V, Bartelink ML, et al. ; European Stroke Organisation; ESC Committee for Practice Guidelines. ESC Guidelines on the diagnosis and treatment of peripheral artery diseases: document covering atherosclerotic disease of extracranial carotid and vertebral, mesenteric, renal, upper and lower extremity arteries: the Task Force on the Diagnosis and Treatment of Peripheral Artery Diseases of the European Society of Cardiology (ESC). Eur Heart J. 2011;32:2851–906.Google Scholar
  51. Tepe G, Schnorr B, Albrecht T, Brechtel K, Claussen CD, Scheller B, Speck U, Zeller T. Angioplasty of femoral-popliteal arteries with drug-coated balloons: 5-year follow-up of the THUNDER trial. JACC Cardiovasc Interv. 2015b;8:102–8.CrossRefPubMedGoogle Scholar
  52. Tepe G, Laird J, Schneider P, et al. Drug-coated balloon versus standard percutaneous transluminal angioplasty for the treatment of superficial femoral and/or popliteal peripheral artery disease: 12-month results from the IN.PACT SFA randomized trial. Circulation. 2015a;131:495–502.CrossRefPubMedPubMedCentralGoogle Scholar
  53. Vemulapalli S, Dolor RJ, Hasselblad V, Schmit K, Banks A, Heidenfelder B, Patel MR, Jones WS. Supervised vs unsupervised exercise for intermittent claudication: a systematic review and meta-analysis. Am Heart J. 2015;169:924–37.CrossRefPubMedGoogle Scholar
  54. Zeller T, Rastan A, Macharzina R, Tepe G, Kaspar M, Chavarria J, Beschorner U, Schwarzwälder U, Schwarz T, Noory E. Drug-coated balloons vs. drug-eluting stents for treatment of long femoropopliteal lesions. J Endovasc Ther. 2014;21:359–68.CrossRefPubMedGoogle Scholar

Copyright information

© Springer International Publishing AG 2017

Authors and Affiliations

  • E. Sebastian Debus
    • 1
  • Reinhart T. Grundmann
    • 2
  1. 1.Department of Vascular MedicineUniversity Heart and Vascular Center at University Clinics Hamburg–EppendorfHamburgGermany
  2. 2.Former Medical DirectorCommunity Hospital Altoetting-BurghausenBurghausenGermany

Personalised recommendations